Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

New canine oral cancer drug to be trialled
Owners of dogs with oral melanoma are being encouraged to participate in the trial.
The drug is already licensed to another form of canine cancer.

A pilot trial is set to be carried out to test the ability of a drug derived from berries to treat canine oral melanoma.

Researchers at the Royal (Dick) School of Veterinary Studies in Edinburgh, Scotland will assess the effectiveness of the drug tigilanol tiglate, which is derived from the berries of the blushwood tree, a species found in Queensland, Australia.

The drug, which disrupts blood vessels inside tumours without harming healthy tissue, is currently licensed to treat mast cell tumours. If it is shown to work to treat canine oral melanoma, it may save some dogs from having to undergo surgery.

The researchers hope that the trial could also provide insights that could benefit human medicine, as canine oral melanoma shares many features with human mucosal melanoma. In both diseases, symptoms typically remain hidden until the disease has already reached an advanced stage.

The research is being funded by QBiotics, the manufacturer of tigilanol tiglate, which it sells under the brand name Stelfonta.

The trial will involve eight dogs, although the number of participating animals may be increased if the initial results prove to be promising. Owners of eligible dogs are being asked to get in touch with the research team.

Kelly Blacklock, professor of small animal soft tissue surgery, said: “If successful, this treatment could transform the way we approach cancer therapy in veterinary medicine, sparing many dogs from the need for surgery.

“We encourage pet owners with dogs diagnosed with oral melanoma to consider participating in this trial. Your involvement could not only contribute to advancing treatment options for this challenging disease but also help improve the quality of life for dogs in the future.”

Eligible dog owners wishing to take part should email Professor Blacklock.

Image © Shutterstock

Become a member or log in to add this story to your CPD history

Animal Medicines Amnesty returns this November

News Story 1
 Veterinary practices are being urged to help owners safely dispose of any unused and expired pet medicines - not just antibiotics - during November's Animal Medicines Amnesty.

Organised by the Responsible Use of Medicines Alliance Companion Animal and Equine (RUMA CA&E), the initative is supported by a range of cross-sector organisations.

Practices are encouraged to use the campaign to engage the whole practice team and raise awareness of the safe disposal of medicines with clients. Learn how your practice can get involved at rumacae.org.uk 

Click here for more...
News Shorts
APHA launches free virtual work experience programme

The Animal and Plant Health Agency (APHA), in collaboration with Springpod, has launched a free virtual work experience programme, giving young people across the UK the chance to explore careers dedicated to protecting animal and plant health.

The on-demand programme offers a unique insight into career opportunities within APHA, showcasing how students can contribute to tackling some of the UK's most critical biosecurity and environmental challenges.

Designed for students aged 13 and over, the course includes more than 10 hours of engaging content featuring real-life industry insights, scenario-based challenges, and practical guidance on applying for jobs. To register for the course, visit the APHA website.